(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 36.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.21%.
Dianthus Therapeutics's earnings in 2025 is -$100,732,000.On average, 16 Wall Street analysts forecast DNTH's earnings for 2025 to be -$110,546,722, with the lowest DNTH earnings forecast at -$120,709,276, and the highest DNTH earnings forecast at -$103,330,022. On average, 15 Wall Street analysts forecast DNTH's earnings for 2026 to be -$116,200,447, with the lowest DNTH earnings forecast at -$155,062,569, and the highest DNTH earnings forecast at -$95,225,707.
In 2027, DNTH is forecast to generate -$127,604,377 in earnings, with the lowest earnings forecast at -$158,844,583 and the highest earnings forecast at -$98,264,825.